

## Product Information

### Monoclonal Anti-Insulin-like Growth Factor-II

#### Clone 75015

produced in mouse, purified immunoglobulin

Catalog Number **I9784**

#### Product Description

Monoclonal Anti-Insulin-like Growth Factor-II (IGF2; mouse IgG1 isotype) is purified from a hybridoma produced by the fusion of mouse myeloma cells and B cells from a mouse immunized with recombinant human Insulin-like Growth Factor-II (GenID 3481) expressed by and purified from *Escherichia coli*. The antibody is purified by Protein G affinity chromatography.

Monoclonal Anti-Insulin-like Growth Factor-II recognizes human Insulin-like Growth Factor-II. This antibody was selected for its ability to neutralize the biological activity of human IGF2.

Insulin-like growth factor-II (also known as multiplication stimulating activity or MSA) and insulin-like growth factor I (IGF-I) belong to the family of insulin-like growth factors, which are structurally homologous to proinsulin. Mature IGF-I and IGF-II are highly conserved and share ~70% amino acid sequence identity. Mouse Igf2, a 67 amino acid protein, has a predicted molecular mass of ~7.4 kDa. Mouse and human IGF-II share 91% sequence identity.

Insulin-like growth factor-II has autocrine, paracrine, and endocrine functions. It is a potent mitogenic growth factor that mediates growth-promoting activities in embryonic development. IGF-II binds the IGF-II receptor with high affinity.

IGF-I and IGF-II are expressed in many tissues and cell types. IGF-II is mitogenic for a variety of cultured cells, including human or chicken fibroblasts, mouse 3T3 cells, normal rat kidney cells, and MCF-7 human breast carcinoma cells.<sup>1</sup>

#### Reagent

Lyophilized from 0.2  $\mu$ m-filtered solution in phosphate buffered saline containing carbohydrates.

#### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

#### Preparation Instructions

To one vial of lyophilized powder, add 1 mL of 0.2  $\mu$ m filtered PBS to produce a 0.5 mg/mL stock solution. If aseptic technique is used, no further filtration should be necessary for use in cell culture environments.

#### Storage/Stability

Prior to reconstitution, store at -20 °C. Reconstituted product may be stored at 2-8 °C for up to one month. For extended storage, freeze in working aliquots at -20 °C. Repeated freezing and thawing, or storage in frost-free freezers, is not recommended.

#### Product Profile

**Neutralization:** To measure the ability of the antibody to neutralize the bioactivity of recombinant human IGF2 on MCF-7 cells, recombinant human IGF2 was incubated with various concentrations of the antibody for 1 hour at 37 °C in a 96 well microplate. Following this preincubation period, MCF-7 cells were added. The assay mixture in a total volume of 100  $\mu$ L, containing antibody at 0.01-500  $\mu$ g/mL, recombinant human IGF2 at 14 ng/mL and cells at  $5 \times 10^4$  cells/mL, was incubated at 37 °C for 72 hours in a humidified CO<sub>2</sub> incubator and pulsed with <sup>3</sup>H-thymidine for the final 24 hours. The cells were subsequently detached, harvested onto glass fiber filters and the <sup>3</sup>H-thymidine incorporated into the DNA was determined.

The Neutralization Dose<sub>50</sub> (ND<sub>50</sub>) for this antibody is defined as that concentration of antibody required to yield one-half maximal inhibition of the cytokine activity on a responsive cell line, when that cytokine is present at a concentration just high enough to elicit a maximum response.

**Note:** In order to obtain the best results using various techniques and preparations, it is recommended to determine the optimal working dilutions by titration.

Endotoxin: <0.1 EU/μg antibody as determined by the LAL method.

**Reference**

1. Zumstein, P., et al., J. Biol. Chem., **262**, 11252 (1987).

RC,PHC,TMS,MAM 06/16-1